143 related articles for article (PubMed ID: 16416330)
41. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
Máthé D; Balogh L; Polyák A; Király R; Márián T; Pawlak D; Zaknun JJ; Pillai MR; Jánoki GA
Nucl Med Biol; 2010 Feb; 37(2):215-26. PubMed ID: 20152721
[TBL] [Abstract][Full Text] [Related]
42. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate.
Blake GM; Park-Holohan SJ; Cook GJ; Fogelman I
Semin Nucl Med; 2001 Jan; 31(1):28-49. PubMed ID: 11200203
[TBL] [Abstract][Full Text] [Related]
43. Atherosclerotic 18F-FDG and MDP uptake in femoral arteries, changes with age.
Bural GG; Torigian D; Rubello D; Alavi A
Nucl Med Commun; 2016 Aug; 37(8):833-6. PubMed ID: 27058364
[TBL] [Abstract][Full Text] [Related]
44. [99m-Tc alendronate as a new option in bone gammagraphy].
Montoya-Molina CE; Sepúlveda-Méndez J; Arteaga-de-Murphy C; Meléndez-Alafort L; Rojas-Bautista JC; López-Alvarenga JC
Rev Invest Clin; 1997; 49(5):373-7. PubMed ID: 9527697
[TBL] [Abstract][Full Text] [Related]
45. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications.
Wong KK; Piert M
J Nucl Med; 2013 Apr; 54(4):590-9. PubMed ID: 23482667
[TBL] [Abstract][Full Text] [Related]
46. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
47. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.
Anderson PM; Subbiah V; Rohren E
Adv Exp Med Biol; 2014; 804():291-304. PubMed ID: 24924181
[TBL] [Abstract][Full Text] [Related]
48. Effects of 99mTc-MIBI and 99mTc-MDP administration on dual-energy X-ray absorptiometry bone mineral density measurements.
Gumuser G; Parlak Y; Topal G; Aras F; Ruksen E; Sayit E
Nucl Med Commun; 2009 Jun; 30(6):445-8. PubMed ID: 19357550
[TBL] [Abstract][Full Text] [Related]
49. 99Tcm-DTPMP as a skeletal scintigraphy agent: distribution in rats in comparison with 99Tcm-MDP.
Láznícek M; Láznícková A; Budský F
Nucl Med Commun; 1996 Dec; 17(12):1016-20. PubMed ID: 9004296
[TBL] [Abstract][Full Text] [Related]
50. The value of local 99mTc(Sn)-MDP bone to soft tissue uptake ratio in osteoporosis, before and during fluoride therapy.
Raymakers JA; Savelkoul TJ; Hoekstra A; Visser WJ; van Rijk PP; Duursma SA
Eur J Nucl Med; 1990; 16(3):157-60. PubMed ID: 2364958
[TBL] [Abstract][Full Text] [Related]
51. Skeletal PET with 18F-fluoride: applying new technology to an old tracer.
Grant FD; Fahey FH; Packard AB; Davis RT; Alavi A; Treves ST
J Nucl Med; 2008 Jan; 49(1):68-78. PubMed ID: 18077529
[TBL] [Abstract][Full Text] [Related]
52. An in vitro model for the comparative evaluation of bone seeking pharmaceuticals.
Mitterhauser M; Toegel S
ALTEX; 2008; 25(1):51-5. PubMed ID: 18360728
[TBL] [Abstract][Full Text] [Related]
53. Predicting detectability in radioguided surgery: a study based on physical characterization of the probe and on tissue uptake ratios of 125I-, 153Sm- and 165Er-labelled radiopharmaceuticals.
Hassfjell SP; Skretting A; Bruland OS; Hoff P
Nucl Med Commun; 1998 Mar; 19(3):207-17. PubMed ID: 9625495
[TBL] [Abstract][Full Text] [Related]
54. [A case of lung cancer updating 99mTc-MDP].
Deng HY; Liang CH; Hu H
Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):inside-cover. PubMed ID: 12575366
[No Abstract] [Full Text] [Related]
55. Validation of ultrafiltration as a method of measuring free 99mTc-MDP.
Moore AE; Hain SF; Blake GM; Fogelman I
J Nucl Med; 2003 Jun; 44(6):891-7. PubMed ID: 12791815
[TBL] [Abstract][Full Text] [Related]
56. SPECT-CT for characterization of extraosseous uptake of 99mTc-methylene diphosphonate on bone scintigraphy.
Soundararajan R; Naswa N; Sharma P; Karunanithi S; Nazar AH; Das KJ; Bal C; Malhotra A; Kumar R
Diagn Interv Radiol; 2013; 19(5):405-10. PubMed ID: 23748034
[TBL] [Abstract][Full Text] [Related]
57. Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [(68)Ga]-EDTMP formulations.
Toegel S; Wadsak W; Mien LK; Viernstein H; Kluger R; Eidherr H; Haeusler D; Kletter K; Dudczak R; Mitterhauser M
Eur J Pharm Biopharm; 2008 Feb; 68(2):406-12. PubMed ID: 17611088
[TBL] [Abstract][Full Text] [Related]
58. Uptake of ethylenediamine tetramethylene phosphonic acid in normal bone after multiple applications. A non-human primate study.
Dormehl IC; Louw WK; Schneeweiss FH; Milner R; Schmitt G; Carl U; Croft SA
Arzneimittelforschung; 1998 Apr; 48(4):408-14. PubMed ID: 9608885
[TBL] [Abstract][Full Text] [Related]
59. Effect of asiaticoside on 99mTc-tetrofosmin and 99mTc-sestamibi uptake in MCF-7 cells.
Al-Saeedi FJ; Bitar M; Pariyani S
J Nucl Med Technol; 2011 Dec; 39(4):279-83. PubMed ID: 22080437
[TBL] [Abstract][Full Text] [Related]
60. 99mTc-MDP uptake and histological changes during rat bone marrow regeneration.
Chisin R; Gazit D; Ulmansky M; Laron A; Atlan H; Sela J
Int J Rad Appl Instrum B; 1988; 15(4):469-76. PubMed ID: 3255743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
